Last C$0.32 CAD
Change Today -0.02 / -5.97%
Volume 1.2M
SDI On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Toronto
As of 3:59 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

spectral diagnostics inc (SDI) Snapshot

Open
C$0.35
Previous Close
C$0.34
Day High
C$0.35
Day Low
C$0.29
52 Week High
11/12/13 - C$0.77
52 Week Low
04/24/13 - C$0.18
Market Cap
42.4M
Average Volume 10 Days
380.8K
EPS TTM
C$-0.09
Shares Outstanding
134.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRAL DIAGNOSTICS INC (SDI)

Related News

No related news articles were found.

spectral diagnostics inc (SDI) Related Businessweek News

No Related Businessweek News Found

spectral diagnostics inc (SDI) Details

Spectral Diagnostics Inc. engages in the development and commercialization of theranostic treatment for severe sepsis and septic shock in North America. Its products include Endotoxin Activity Assay for the identification of patients at risk of developing sepsis and certain proprietary biological reagents; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. The company also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. Spectral Diagnostics Inc. was founded in 1991 and is headquartered in Toronto, Canada.

20 Employees
Last Reported Date: 03/27/14
Founded in 1991

spectral diagnostics inc (SDI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$424.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: C$265.6K
Vice President of Clinical Development
Total Annual Compensation: C$201.8K
Vice President of Sales and Marketing
Total Annual Compensation: C$117.8K
Compensation as of Fiscal Year 2013.

spectral diagnostics inc (SDI) Key Developments

Spectral Diagnostics Inc. Updates Status of EUPHRATES Trial

Spectral Diagnostics Inc. announced that the Data Safety Monitoring Board for the EUPHRATES trial has completed its review of the detailed analysis it had previously requested. Based on the current recommendations of the DSMB, the sample size has been recalculated and increased from 360 to 650 patients. This increase in the number of enrolled patients enhances the likelihood of demonstrating, with sufficient power, a statistically and clinically significant effect. The revised sample size falls within the statistical plan already agreed to by the United States Food and Drug Administration (FDA). Spectral will also promptly submit a protocol amendment to the FDA, as recommended by the DSMB, for an additional exclusion criterion. The EUPHRATES trial has continued to enrol patients and, as of April 11, 2014, 271 patients have been randomized.

Spectral Diagnostics Inc. Announces Audited Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Spectral Diagnostics Inc. announced audited earnings results for the fourth quarter and year ended December 31, 2013. For the quarter the company reported revenue was CAD 713,000 compared to CAD 647,000 for the same three month period last year. Loss was CAD 3,673,000 or CAD 0.03 per share compared to CAD 2,067,000 or CAD 0.02 per share for the same quarter last year. For the year, the company reported revenue was CAD 2,672,000 compared to CAD 2,589,000 for the prior year, representing an increase of CAD 83,000. Loss of CAD 11,307,000, or CAD 0.09 per share, compared to a loss of CAD 8,543,000 or CAD 0.08 per share, for the year ended December 31, 2012. Operating loss was CAD 11,366,000 compared to CAD 8,614,000 in the same period last year. Net cash used in operating activities was CAD 9,191,000 compared to CAD 7,725,000 in the same period last year. Property, plant and equipment expenditures CAD 343,000 compared to CAD 269,000 in the same period last year.

Spectral Diagnostics Inc. Auditor Raises 'Going Concern' Doubt

Spectral Diagnostics Inc. filed its Annual on Mar 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SDI:CN C$0.32 CAD -0.02

SDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SDI.
View Industry Companies
 

Industry Analysis

SDI

Industry Average

Valuation SDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.3x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRAL DIAGNOSTICS INC, please visit www.spectraldx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.